Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 7 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Editas Medicine Inc. currently manages 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 14 actions are distributed across 14 distinct examiners, which means that every single pending matter is being reviewed by a different individual. The 7 distinct art units involved indicate that the company's intellectual property spans several specialized examination groups, requiring a strategy that accounts for different procedural nuances within the patent office.
Among the active personnel, Meah, Mohammad Y is identified as the busiest examiner, currently overseeing 1 of the pending office actions. This assignment of 1 action to each examiner, including Meah, Mohammad Y, highlights a completely decentralized prosecution environment for the portfolio. For a practitioner, the presence of 14 pending office actions across 7 distinct art units necessitates a versatile approach to prosecution, as each unit may apply different interpretations of Biotechnology & Pharmaceuticals guidelines.
The fact that 14 distinct examiners are handling 14 pending office actions implies that no institutional knowledge gained from one prosecution will carry over to others through examiner overlap. This lack of overlap, where Meah, Mohammad Y and all other examiners manage only 1 pending action, means that individual examiner preferences will dictate the outcome of every case. Consequently, the 14 pending office actions represent a fragmented landscape where practitioners must engage with 14 different individuals across 7 distinct art units.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (21%) |
| §103 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 4 (29%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| BABIC, CHRISTOPHER M | 1 | 60.6% | +23.6% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 40d |
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | — |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | — |
| 16899302 | CPF1-RELATED METHODS AND COMPOSITIONS FOR GENE EDITING | WESTON, ALYSSA G | — |
| 16098845 | GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | SULLIVAN, STEPHANIE LAUREN | 114d overdue |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 92d overdue |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 70d overdue |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | — |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | — |
| 18555716 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | HUDSON, AMY ROSE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1632 | 3 |
| 1638 | 2 |
| 1633 | 2 |
| 1635 | 2 |
| 1652 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | 1652 | §103§112 | Non-Final OA | — | Pending | Feb 17, 2026 |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | 1636 | §101§103§112DPOther | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 12, 2023 |
| 18555716 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | HUDSON, AMY ROSE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 1636 | §103 | Final Rejection | 70d overdue | Pending | Nov 28, 2022 |
| 17836165 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | MONTANARI, DAVID A | 1632 | DP | Non-Final OA | — | Pending | Jun 09, 2022 |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 1632 | §103Other | Final Rejection | 92d overdue | Pending | Feb 07, 2022 |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | 53d overdue | Pending | Jan 10, 2022 |
| 17412608 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | BABIC, CHRISTOPHER M | 1633 | §103DP | Final Rejection | — | Pending | Aug 26, 2021 |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | SULLIVAN, STEPHANIE LAUREN | 1635 | §103DP | Final Rejection | 114d overdue | Pending | Aug 25, 2021 |
| 17430382 | MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY | GRABER, JAMES J | 1631 | §102§103§112DP | Final Rejection | 56d overdue | Pending | Aug 12, 2021 |
| 16899302 | CPF1-RELATED METHODS AND COMPOSITIONS FOR GENE EDITING | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jun 11, 2020 |
| 16098845 | GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME | VIVLEMORE, TRACY ANN | 1638 | §101§103§112 | Final Rejection | — | Pending | Nov 02, 2018 |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §101§103§112 | Non-Final OA | 40d | Pending | Oct 12, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial